<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760849</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0814</org_study_id>
    <secondary_id>NCI-2016-00778</secondary_id>
    <secondary_id>2015-0814</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02760849</nct_id>
  </id_info>
  <brief_title>Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations</brief_title>
  <official_title>WISP (Women Choosing Surgical Prevention)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well surgery works in preventing ovarian cancer in patients
      with genetic mutations at risk of ovarian cancer. Risk reducing salpingo oophorectomy (RRSO)
      is surgery to remove the fallopian tubes and ovaries at the same time. Interval salpingectomy
      with delayed oophorectomy (ISDO) is surgery to remove the fallopian tubes. It is not known
      whether ISDO works better than RRSO at lowering risk of ovarian cancer and improving the
      sexual function and psychosocial well-being in patients with genetic mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To examine changes in female sexual function with the strategy of interval salpingectomy
      and delayed oophorectomy (ISDO) compared to the strategy of risk-reducing
      salpingo-oophorectomy (RRSO) for patients who carry genetic mutations that predispose them to
      ovarian cancer.

      SECONDARY OBJECTIVES:

      I. To estimate the onset and severity of menopausal symptoms with ISDO compared to RRSO.

      II. To estimate quality of life with ISDO compared to RRSO. III. To examine participants'
      satisfaction level and cancer worry level with their choice of prophylactic procedures.

      IV. To estimate the impact of ISDO compared to RRSO on mental health, including depression,
      anxiety, and sleep quality.

      V. To determine the compliance with ISDO compared to RRSO. VI. To estimate the number of
      fallopian tube, ovarian, or primary peritoneal malignancies and other malignancies over the
      course of the study.

      OUTLINE: Patients are assigned to 1 of 2 arms.

      ARM I: Patients undergo ISDO.

      ARM II: Patients undergo RRSO.

      After completion of study treatment, patients are followed up at 1 and 6 months, 1 year, and
      2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2042</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2041</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of women with clinically meaningful change in the Female Sexual Function Index (FSFI) score</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Will be calculated using the Cochran-Mantel-Haenszel test stratified by age, with 5-year age groups. We will use propensity score methods to account for potential differences between interval salpingectomy with delayed oophorectomy (ISDO) and risk-reducing bilateral salpingectomy with oophorectomy (RRSO) arms with respect to age, baseline survey scores, and other potential confounders, and we will use the propensity scores as inverse weights in logistic regression to model the logit of the probability of having a clinically meaningful change in FSFI score from baseline to 6 months as our primary analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Deleterious BARD1 Gene Mutation</condition>
  <condition>Deleterious BRCA1 Gene Mutation</condition>
  <condition>Deleterious BRCA2 Gene Mutation</condition>
  <condition>Deleterious BRIP1 Gene Mutation</condition>
  <condition>Deleterious EPCAM Gene Mutation</condition>
  <condition>Deleterious MLH1 Gene Mutation</condition>
  <condition>Deleterious MSH2 Gene Mutation</condition>
  <condition>Deleterious MSH6 Gene Mutation</condition>
  <condition>Deleterious PALB2 Gene Mutation</condition>
  <condition>Deleterious PMS2 Gene Mutation</condition>
  <condition>Deleterious RAD51C Gene Mutation</condition>
  <condition>Deleterious RAD51D Gene Mutation</condition>
  <condition>Hereditary Breast and Ovarian Cancer Syndrome</condition>
  <condition>Premenopausal</condition>
  <arm_group>
    <arm_group_label>Arm I (ISDO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo ISDO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (RRSO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo RRSO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (ISDO)</arm_group_label>
    <arm_group_label>Arm II (RRSO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oophorectomy</intervention_name>
    <description>Undergo ISDO</description>
    <arm_group_label>Arm I (ISDO)</arm_group_label>
    <other_name>Female Castration</other_name>
    <other_name>Ovariectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (ISDO)</arm_group_label>
    <arm_group_label>Arm II (RRSO)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salpingectomy</intervention_name>
    <description>Undergo ISDO</description>
    <arm_group_label>Arm I (ISDO)</arm_group_label>
    <other_name>Tubal Excision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salpingo-Oophorectomy</intervention_name>
    <description>Undergo RRSO</description>
    <arm_group_label>Arm II (RRSO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women with a documented deleterious mutation in one of the following
             ovarian cancer genes: BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6,
             MLH1, or PMS2, or EPCAM; (please note: menopause is defined as &gt;= 12 months of
             amenorrhea; however, for those patients with &gt;= 12 months of amenorrhea who may be
             pre-menopausal, levels of follicle-stimulating hormone [FSH], luteinizing hormone
             [LH], and estradiol in the pre-menopausal range will be acceptable)

          -  Willing to undergo two surgical procedures (if participant chooses the ISDO arm)

          -  Presence of at least 1 fallopian tube and 1 ovary; (please note: prior unilateral
             salpingectomy is allowed; prior bilateral salpingectomy is not allowed)

          -  Patients who have undergone a prior tubal ligation will be eligible

          -  Participants may have a personal history of non-ovarian malignancy, but must: a) be
             without evidence of disease at enrollment b) remain premenopausal c) have completed
             treatment (including surgery, chemotherapy, radiotherapy or hormonal therapy) &gt; 3
             months prior to enrollment (other than non-melanoma skin cancer)

          -  Willingness to return to the enrolling site for the study surgical procedures,
             including pre-operative and post-operative care; (patients in the ISDO arm must be
             willing to return to the enrolling site for yearly ovarian cancer assessment)

          -  Patients must understand that they will be permanently sterilized

        Exclusion Criteria:

          -  Women with a personal history of ovarian, fallopian tube, or primary peritoneal cancer

          -  Current treatment with tamoxifen or aromatase inhibitors

          -  Medical comorbidities making surgery unsafe as determined by the patient's surgeon

          -  Women who are pregnant or post-partum (within 3 months of delivery); patients are
             deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound,
             beta human chorionic gonadotropin (HCG), or best judgement of the investigator;
             pregnancy testing is not required per protocol to determine study eligibility; women
             who become pregnant on the ISDO arm via reproductive technology can remain on study;
             however, data collection will be suspended during pregnancy and 3 months post-partum

          -  Women with elevated levels of CA125 (&gt; 50) or transvaginal ultrasound suggesting
             cancer, unless findings are consistent with endometriosis; CA125 and transvaginal
             ultrasounds must be the most recent, but no older than 1 year from the date of
             enrollment

          -  Inability to provide informed consent

          -  Inability to read or speak English
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen H Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Lu, MD</last_name>
    <phone>(713) 745-8902</phone>
    <email>khlu@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris L. Romero</last_name>
      <phone>773-703-3972</phone>
      <email>iromero@babies.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Iris L. Romero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil S. Horowitz</last_name>
      <phone>617-632-3743</phone>
      <email>nhorowitz@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Neil S. Horowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie N. Bakkum-Gamez</last_name>
      <phone>507-293-1487</phone>
      <email>bakkum.jamie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie N. Bakkum-Gamez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea R. Hagemann</last_name>
      <email>hagemanna@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea R. Hagemann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas A. Levine</last_name>
      <phone>646-501-4834</phone>
      <email>Douglas.levine@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Douglas A. Levine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara C. Long Roche</last_name>
      <phone>212-639-7043</phone>
      <email>longrock@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Kara C. Long Roche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah H. Kim</last_name>
      <phone>215-662-3318</phone>
      <email>skim@obgyn.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah H. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen H. Lu</last_name>
      <phone>832-750-1796</phone>
      <email>WISP@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Karen H. Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth M. Swisher</last_name>
      <phone>206-685-7927</phone>
      <email>swishere@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth M. Swisher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://wisp.mdanderson.org</url>
    <description>WISP University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

